CalciMedica (CALC) CFO Stephen Bardin Receives 190,000-Share Award

What Happened
Stephen Bardin, Chief Financial Officer of CalciMedica, was granted 190,000 derivative shares (reported acquisition price $0.00) on September 24, 2026. The Form 4 lists the transaction as an award/grant (code A) rather than a market purchase or sale, so there was no cash outlay by Bardin and no immediate sale of shares.

Key Details

• Transaction date: 2026-09-24; Form 4 filed: 2026-09-28 (filed within the standard 2 business-day window).
• Security: 190,000 derivative shares reported as acquired at $0.00 (award/grant).
• Shares owned after transaction: Not specified in the filing.
• Vesting: Begins 2026-09-24; 1/48th of the award vests each month over four years (per footnote).
• Transaction type code: A (Grant/Award). No 10b5-1, tax withholding, or cashless exercise noted.

Context
This is an equity compensation award to an executive, commonly used to align management with shareholder interests. Because the filing reports a derivative award with scheduled vesting, these shares are subject to future vesting rather than being immediately tradeable. Awards at $0.00 on the Form 4 typically reflect grants of options or restricted stock units; the filing does not specify an immediate monetary value or indicate any sale.